Tilray Inc (NASDAQ:TLRY) Given Average Rating of “Hold” by Brokerages

Shares of Tilray Inc (NASDAQ:TLRY – Get Rating) have been given a consensus rating of “Hold” by the twelve analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $8.31.

Several brokerages recently weighed in on TLRY. Canaccord Genuity Group cut their target price on shares of Tilray from $9.00 to $7.00 in a research note on Wednesday, June 15th. Cantor Fitzgerald upped their target price on shares of Tilray from $6.90 to $8.40 and gave the stock a “neutral” rating in a research note on Thursday, April 7th. Piper Sandler cut their target price on shares of Tilray from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday, June 15th. Barclays cut their target price on shares of Tilray from $8.50 to $4.50 and set an “underweight” rating on the stock in a research note on Wednesday, April 20th. Finally, Canaccord Genuity Group raised shares of Tilray from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a research note on Friday, March 4th.

Shares of TLRY stock opened at $3.58 on Friday. The firm’s 50 day moving average price is $4.45 and its 200-day moving average price is $5.89. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.50 and a current ratio of 2.46. Tilray has a one year low of $3.02 and a one year high of $19.24. The firm has a market cap of $1.78 billion, a P/E ratio of 18.84 and a beta of 2.54.

Tilray (NASDAQ:TLRY – Get Rating) last issued its quarterly earnings data on Wednesday, April 6th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.12. Tilray had a net margin of 6.80% and a negative return on equity of 0.78%. The firm had revenue of $151.90 million for the quarter, compared to analyst estimates of $156.64 million. Tilray’s quarterly revenue was up 22.6% on a year-over-year basis. As a group, research analysts predict that Tilray will post -0.17 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of TLRY. Renaissance Technologies LLC purchased a new position in shares of Tilray in the 4th quarter valued at $36,646,000. Dimensional Fund Advisors LP grew its position in shares of Tilray by 581.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,040,461 shares of the company’s stock valued at $45,617,000 after buying an additional 3,447,611 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Tilray by 11,440.5% in the 4th quarter. Cubist Systematic Strategies LLC now owns 1,026,876 shares of the company’s stock valued at $7,219,000 after buying an additional 1,017,978 shares during the last quarter. Prentice Capital Management LP purchased a new position in shares of Tilray in the 1st quarter valued at $5,293,000. Finally, Qube Research & Technologies Ltd grew its position in shares of Tilray by 2,914.7% in the 4th quarter. Qube Research & Technologies Ltd now owns 673,477 shares of the company’s stock valued at $4,735,000 after buying an additional 651,137 shares during the last quarter. 13.84% of the stock is currently owned by hedge funds and other institutional investors.

Tilray Company Profile (Get Rating)

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Featured Stories